Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
Open Access
- 1 January 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (1) , 47-50
- https://doi.org/10.1093/annonc/mdi012
Abstract
The tumour marker CA125 is an important indicator of the clinical progress of women with carcinoma of the ovary. We have investigated the interval from the nadir CA125 value to progression defined by rising CA125 (time to biochemical progression, TBP), and overall survival of patients treated with chemotherapy for this disease in relation to the nadir CA125 value in patients in whom this was P < 0.001). This was associated with similar differences for overall survival, the median was 2968 days in group A, 537 days in group B and 537 days in group C, (P < 0.001). Variations in the CA125 value even within the normal range carry useful information. This prognostic indicator will be useful in studying the management of patients following response to first-line chemotherapy.Keywords
This publication has 7 references indexed in Scilit:
- Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group TrialJournal of Clinical Oncology, 2003
- Ovarian cancer: progress and continuing controversies in managementEuropean Journal Of Cancer, 2002
- Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated LevelsJournal of Clinical Oncology, 2001
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]JNCI Journal of the National Cancer Institute, 2000
- CA125 production by the peritoneum: in-vitro and in-vivo studiesHuman Reproduction, 2000
- What should be the cut-off level of serum CA125 to evaluate the disease status before second-look laparotomy in epithelial ovarian carcinoma?International Journal of Gynecologic Cancer, 1997
- Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markersCancer, 1995